Novo Nordisk India Pvt. Ltd. and Emcure Pharmaceuticals Ltd. have entered into a strategic partnership to launch Poviztra (semaglutide injection 2.4 mg) in India, aiming to strengthen the distribution and marketing of the weight management drug across a wider geographic footprint.
Under the agreement, Emcure Pharma will serve as the exclusive distributor responsible for the commercialisation and marketing of Poviztra in India. The move is intended to expand access to semaglutide-based therapies beyond regions currently served by Novo Nordisk India, particularly through retail pharmacy networks and regional distribution channels.
Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India in June 2025 as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management and reduction of major adverse cardiovascular events (MACE) in adults with obesity or overweight.
Clinical data showed that one in three participants treated with Wegovy achieved over 20% body weight reduction. Poviztra is being introduced as a second brand of Wegovy to further enhance accessibility.
“Obesity is a serious chronic disease affecting millions of people across India and results in significant unmet medical needs,” said Jay Thyagarajan, Senior Vice President, Region APAC, Novo Nordisk. “This partnership brings together Novo Nordisk’s innovation in GLP-1 therapies and Emcure’s strong marketing and distribution capabilities to improve access to high-quality, safe, and effective obesity treatments.”
Poviztra is indicated as an adjunct to lifestyle modification for chronic weight management in adults with a BMI ≥30 kg/m² (obesity) or ≥27 kg/m² (overweight) with at least one weight-related comorbidity. It is also approved for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease who are overweight or obese.
The once-weekly pre-filled pen device is available in five dose strengths — 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg (maintenance) — designed for ease of use and precise dosing.
India is estimated to have 254 million people with generalised obesity and an additional 351 million with abdominal obesity. Obesity is associated with over 230 health complications, including cardiovascular disease, fatty liver, osteoarthritis, and kidney disease.
Experts note that obesity is multifactorial, driven by genetics, biology, environment, and psychology — and, like diabetes or asthma, requires long-term medical management rather than short-term lifestyle fixes.
Founded in 1994, Novo Nordisk India is the Indian affiliate of Novo Nordisk A/S, a Denmark-based global healthcare company established in 1923, known for leadership in diabetes care and metabolic diseases.
Emcure Pharmaceuticals Ltd., headquartered in Pune, is among India’s leading pharmaceutical companies, engaged in developing, manufacturing, and marketing a wide range of prescription medicines globally. The company focuses on innovation-driven growth and patient-centric solutions across major therapeutic areas.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!